Published online Jul 16, 2022. doi: 10.4253/wjge.v14.i7.416
Peer-review started: February 28, 2022
First decision: April 13, 2022
Revised: May 8, 2022
Accepted: June 15, 2022
Article in press: June 15, 2022
Published online: July 16, 2022
High-grade bleeding and perforation are some of the side effects of antiangiogenic agents. The safety of endoscopy in patients receiving this therapy is unknown. Here we attempt to explore the incidence of bleeding, perforation, and mortality in our single centered study.
With the increased survival rate of cancer patients with newer chemotherapy, more patients would require endoscopic procedures for further surveillance and screening. It is important to assess the safety of endoscopic procedures among patients receiving therapy such as antiangiogenic agents who are at higher risk for bleeding and perforation.
To understand the risk of endoscopy in patients on antiangiogenic agents.
We performed a retrospective analysis of patients, on antiangiogenic agents, who were admitted to the hospital at our institute. We used simple descriptive statistics to primarily assess mortality within 30 d of the procedure along with the incidence of bleeding and perforation.
We found no procedure-related adverse events in our small population study among the patients receiving antiangiogenic agents. These results need to be further confirmed in a multicentric larger population group.
Our study reveals that endoscopic procedures are safe in patients receiving antiangiogenic agents. It affirms to not delay emergent or urgent endoscopic procedures among this population.
Future research should be carried out in a multicentric and larger group of the population than the one in this study to further assess the safety of the endoscopic procedure among this population group.